Anifro-Dazuk comparison

Description

Both dazukibart and anifrolumab target the type I interferon axis in dermatomyositis, but they do it at different “levels” (one neutralizes IFN-β, the other blocks the type I IFN receptor), and the quality/amount of dermatomyositis-specific outcome data is very different.

Explanation

1) Mechanism and what that implies

• Dazukibart: a selective monoclonal antibody that neutralizes IFN-β (upstream cytokine neutralization).
• Anifrolumab: a monoclonal antibody to IFNAR1 (type I IFN receptor subunit 1), therefore blocks signaling from multiple type I interferons, not just IFN-β.

Practical implication: receptor blockade is “broader” interferon suppression, which is biologically attractive in interferon-driven phenotypes, but can plausibly come with *more viral infection signal *(e.g., zoster), something already familiar from the lupus program and echoed in dermatomyositis real-world reports.

2) Dazukibart dermatomyositis results (best-quality DM data: randomized phase 2)

This is the key point: dazukibart already has randomized, placebo-controlled dermatomyositis efficacy data with a prespecified endpoint.

Trial design (phase 2, multicenter, double-blind, placebo-controlled):

• Adults 18–80; largely skin-predominant DM (CDASI-A ≥14 and ≥1 failed systemic therapy), plus a smaller muscle-predominant cohort mainly for safety.
• N treated: 75 (150 mg n=15; 600 mg n=37; placebo n=23).
• Dosing: IV every 4 weeks (through week 8 for the first 12-week comparison).

Primary endpoint (skin-predominant): CDASI-A change at week 12

• Stage 1: mean CDASI-A change with 600 mg: −18.8, placebo-adjusted difference −14.8, p<0.0001.
• Pooled skin set:
  • 600 mg: −19.2, placebo-adjusted difference −16.3, p<0.0001
  • 150 mg: −16.6, placebo-adjusted difference −13.7, p<0.0001

Safety signal (week 12 comparison)

• Treatment-emergent AEs: ~80% across dazukibart and placebo arms (similar overall rates).
• “Infections and infestations” were the most common: 13% (150 mg) vs 32% (600 mg) vs 30% (placebo).
• Serious AEs: 11% (150 mg) vs 4% (placebo) reported in the abstract.
• One death in the muscle-predominant stage 3 sequence: HLH/MAS during follow-up.

Muscle domain (limited conclusions)

• The phase 2 program was not powered around a muscle efficacy primary endpoint; commentary notes non-significant MMT-8 improvement with significant CK reduction in the muscle-predominant cohort.

3) Anifrolumab dermatomyositis results (so far: real-world series + case reports; RCT underway)

For dermatomyositis, anifrolumab does not yet have completed, peer-reviewed randomized efficacy results comparable to dazukibart’s phase 2 DM RCT. What we have is encouraging but lower-evidence data:

Largest reported DM series (retrospective, compassionate use; ACR Convergence 2025)

• 24 refractory DM patients, most treated for cutaneous refractoriness (≈92%).
• Dose: typically 300 mg every 4 weeks (one juvenile patient 150 mg q4w).
• Follow-up: mean 7.5 ± 4.2 months.
• Outcomes reported qualitatively: marked cutaneous improvement (CDASI) and muscle stability (MMT8)(figures shown but numeric deltas not provided in the abstract text).
• AEs: impetigo (1), arthralgia/myalgia (1), UTI (2), herpes zoster (1); no discontinuations due to AEs (one stopped due to loss to follow-up).

Case-level evidence (examples)

• Refractory DM/antisynthetase overlap: “significant improvement” in skin and myopathy within ~5 months after adding anifrolumab (case report).
• Anti-MDA5+ DM case report: improvement in ulcers/arthritis and reported radiographic + physiologic improvement in ILD after multiple infusions; no AEs reported in that case.

Randomized trial in IIM (including DM) is in progress

• Phase 3 JASMINE: ~240 participants, SC weekly anifrolumab vs placebo added to standard of care; started June 20, 2024; primary completion currently listed May 14, 2027.

Result: side-by-side comparison (what you can and cannot conclude)

My bottom line

• If you’re comparing study results, dazukibart currently “wins” on strength of evidence and quantified skin effect size in dermatomyositis, because it already has a placebo-controlled phase 2 DM signal with large CDASI-A improvements at 12 weeks.
• Anifrolumab has promising—but uncontrolled—signals (largest being a 24-patient retrospective series) and an active phase 3 trial that should finally provide comparable, interpretable effect sizes and domain-specific outcomes.

Mechanistic frame (why phenotype matters)

• Dazukibart is a selective IFN-β neutralizing IgG1 strategy (upstream, single ligand).
• Anifrolumab blocks type I interferon receptor (IFNAR1) (downstream, blocks signaling of multiple type I IFNs), which may matter when the dominant interferon “flavor” varies by DM phenotype/autoantibody.

1) Skin-predominant, refractory cutaneous DM (the most “apples-to-apples” phenotype)

Dazukibart (phase 2, placebo-controlled; skin-predominant stages)

Entry phenotype: “skin predominant” with CDASI activity ≥14 and prior medication failure.

Week 12 outcome (CDASI activity change):

• 600 mg: −19.18
• 150 mg: −16.59
• Placebo: −2.93

Interpretation: clear signal vs placebo for cutaneous disease activity at 12 weeks in a refractory skin-predominant cohort.

Anifrolumab (multicenter retrospective “real-world”; largely cutaneous-driven initiation)

All patients had refractory cutaneous disease; CDASI-A available in 21 patients.

Median CDASI-A trajectory:

• Baseline 23.0 → 6.0 at month 1 → 4.0 at month 3 → 2.5 at month 6 (sustained to month 12).
• At 6 months, feature-level improvement rates included heliotrope 91%, Gottron 89%, pruritus 83%.

Interpretation: very rapid and sustained cutaneous improvement, but without a placebo comparator.

Practical synthesis for the skin-predominant phenotype

• If you want placebo-controlled cutaneous efficacy, the strongest DM-specific evidence (today) is dazukibart in skin-predominant disease.
• If you want real-world speed + multi-domain improvement (skin + steroid-sparing + other organs), anifrolumab shows a striking early CDASI drop (month 1) and sustained low activity.

2) Muscle-predominant / myopathic DM

Dazukibart (muscle-predominant stage)

Entry phenotype: “muscle predominant” active disease (criteria include MMT-8 and global assessments).

Outcome (TIS, 0–100): higher TIS vs placebo across weeks 4–12; at week 12:

• Dazukibart 600 mg: 56.4
• Placebo: 36.9

Anifrolumab (real-world myopathic subgroup)

In the subgroup with baseline weakness, MMT-8 improved from 142.5 at baseline to 146.5 at month 1 and 150.0 at month 3 (sustained thereafter), with statistically significant gains vs baseline at months 1, 3, and 6.

Interpretation:

• Dazukibart provides controlled evidence of improvement on a composite myositis response metric (TIS).
• Anifrolumab shows clinically meaningful MMT-8 improvement in routine care, with accompanying CK reduction described in the cohort.

3) Amyopathic DM

This is where anifrolumab currently has explicit phenotype representation, and dazukibart is hard to phenotype-stratify from accessible materials.

• Anifrolumab cohort: amyopathic 37% (11/30).
• The reported CDASI improvements apply to the overall cohort; the paper does not (in the excerpted sections) present separate amyopathic-only CDASI curves.
• Dazukibart: the Pfizer plain-language summary cleanly separates skin-predominant vs muscle-predominant, but does not provide amyopathic vs classic breakdown.

Clinical inference (careful): for amyopathic DM, today’s reported phenotype-specific experience is stronger for anifrolumab simply because the cohort explicitly includes many amyopathic patients.

4) Juvenile DM

• Anifrolumab cohort: juvenile 10% (3/30).
• Dazukibart study: adults only in the described program.

So if you’re asking “any evidence at all in juvenile phenotype,” anifrolumab has limited real-world exposure; dazukibart evidence here is not represented in these adult trial summaries.

5) Antisynthetase overlap and ILD-involved phenotypes

Anifrolumab (has explicit ASyS and ILD reporting)

• ILD present in 20% (6/30).
• PFTs (available in 3) were stable in 2 and improved in 1; imaging showed improvement in 1 and stability in others.
• ASyS subgroup (n=3): all anti-PL-7, all had pulmonary/articular/muscular involvement; after anifrolumab, skin improved, muscle improved or stabilized, pulmonary unchanged during follow-up.

Dazukibart

In the accessible sources here, I can’t extract ILD/ASyS subgroup outcomes (the detailed trial appendix appears access-restricted from this environment), so I won’t invent those results. What we can say is that the program separated skin-predominant from muscle-predominant cohorts and demonstrated benefit on CDASI and TIS, respectively.

Bottom line: For ASyS/ILD phenotypes, anifrolumab currently has directly described (though small-N) data; dazukibart phenotype-specific ILD results are not retrievable from the sources available here.

6) Autoantibody / paraneoplastic phenotypes (TIF1γ, MDA5, SAE1, etc.)

Anifrolumab: antibody-stratified cohort composition is clear

• MSA-positive 83%
  • Anti-TIF1γ 40%
  • Anti-SAE-1 17%
  • Anti-MDA5 10%
  • Anti-PL-7 10%
  • plus smaller numbers of Mi-2 and Jo-1.
• Paraneoplastic phenotype 20% (6/30).

Dazukibart: autoantibody-stratified outcomes not available in the accessible summary

The trial and commentary support IFN-β inhibition as a promising strategy in adult DM, but the plain-language results summary does not provide MSA-stratified efficacy tables.

What you can do clinically with this today

• If your phenotype lens is primarily TIF1γ-associated skin disease or mixed cutaneous/systemic phenotypes, anifrolumab has documented exposure with that autoantibody being the largest subgroup (40%).
• If your lens is “refractory cutaneous DM regardless of antibody” and you want controlled efficacy, dazukibart has the cleaner placebo-controlled cutaneous signal—but the antibody-by-antibody question can’t be answered from the accessible trial summary.

7) Prior JAK inhibitor exposure (a practical “treatment-resistant phenotype”)

In the anifrolumab cohort, 53% previously received a JAK inhibitor.

They performed a sensitivity analysis:

• Baseline CDASI-A higher in the “recent JAKi” group, but both groups improved at month 1; the paper provides within-patient changes and between-group differences.

For dazukibart, prior treatment failure is required in skin-predominant cohorts, but prior JAKi-specific stratified outcomes are not provided in the summary.

Safety signals (phenotype-adjacent)

• Dazukibart stage 3: 12/18 reported ≥1 medical problem by week 12; mostly GI; no shingles or oral herpesreported in that stage summary.
• Anifrolumab cohort: adverse events were described as mostly mild in a minority; there was one death in an 89-year-old from pneumonia/respiratory failure.

(Again: cross-study safety comparisons are especially confounded by age, comorbidity, background immunosuppression, and follow-up duration.)

The “phenotype-stratified” takeaway (how I’d summarize to a myositis team)

1. Skin-predominant refractory DM

• Best controlled evidence: dazukibart (CDASI change vs placebo at week 12).
• Best real-world kinetics: anifrolumab (median CDASI-A collapses by month 1; sustained).

1. Muscle-predominant / myopathic DM

• dazukibart: improved TIS vs placebo at week 12.
• anifrolumab: improves MMT-8 in the weak subgroup with early gains.

1. Amyopathic / juvenile / overlap phenotypes

• anifrolumab has explicit representation (amyopathic 37%, juvenile 10%, ASyS 10%).
• dazukibart summaries available here don’t provide those finer phenotype splits beyond skin- vs muscle-predominant.

1. ILD / antisynthetase

• anifrolumab: small-N but directly described stability/improvement (and an ASyS subgroup narrative).
• dazukibart: ILD subgroup outcomes not extractable from accessible materials in this environment.